# Cardiac Viability Assessment

## Concepts of Myocardial Viability

### Why Viability Matters

Patients with ischemic cardiomyopathy and reduced left ventricular ejection fraction face a critical clinical question: will revascularization improve their ventricular function and survival? The answer depends on whether the dysfunctional myocardium is viable -- capable of recovering contractile function -- or replaced by irreversible scar. Viability assessment aims to identify patients who will benefit from revascularization and distinguish them from those better managed with medical therapy alone.

### Hibernating Myocardium

Hibernating myocardium is chronically underperfused tissue that has downregulated its contractile function to match the reduced blood supply, representing an adaptive survival response to chronic ischemia. Despite appearing dysfunctional on imaging and echocardiography, hibernating myocardium maintains cellular integrity and metabolic activity, with preserved or even increased glucose metabolism. After successful revascularization, hibernating myocardium can recover contractile function over weeks to months. Histologically, hibernating myocytes show loss of myofibrils and glycogen accumulation but have intact cell membranes.

### Stunned Myocardium

Stunned myocardium is contractile dysfunction that persists despite restoration of normal blood flow, occurring after acute ischemic events such as acute coronary syndromes, post-PCI, post-CABG, or after exercise-induced ischemia. Unlike hibernation, stunning is transient: function recovers spontaneously over hours to weeks without intervention. The mechanism involves calcium overload and oxidative stress from reperfusion. However, repeated episodes of stunning can lead to chronic hibernation.

### Scar/Fibrosis

Scar represents irreversible myocyte death replaced by fibrous tissue. Scarred myocardium has no metabolic activity and will not recover function after revascularization. Transmural scar leaves no potential for recovery, while non-transmural scar may have an epicardial viable rim with partial recovery potential.

## FDG PET Viability Protocol

### Principle

The basis of FDG PET viability imaging is that viable myocardium maintains glucose metabolism even when perfusion is reduced. The mismatch pattern -- reduced perfusion with preserved FDG uptake -- is the hallmark of hibernating myocardium. The match pattern -- reduced perfusion with proportionally reduced FDG uptake -- indicates scar. Normal perfusion with normal FDG uptake represents normal myocardium.

### Patient Preparation -- Critical Step

Metabolic preparation is the most critical and most commonly failed aspect of cardiac FDG PET. The goal is to shift myocardial substrate utilization from fatty acids to glucose, because under fasting conditions, normal myocardium preferentially metabolizes fatty acids and FDG uptake is heterogeneous and unpredictable. The glucose loading protocol involves an oral glucose load of 25 to 75 g given 45 to 60 minutes before FDG injection, which stimulates insulin secretion and promotes GLUT-4 translocation to the cell membrane. Blood glucose is checked afterward: levels above 250 mg/dL may produce suboptimal results, and small doses of supplemental IV insulin (1 to 2 units, titrated) may be given if glucose is elevated. The insulin clamp protocol is the gold standard but technically complex: an IV insulin infusion with concurrent glucose administration maintains euglycemia at approximately 100 mg/dL, producing the most reliable and uniform myocardial FDG uptake. A third option, the nicotinic acid derivative (acipimox) protocol used in some European centers, inhibits lipolysis to reduce free fatty acid levels, promoting glucose utilization when combined with an oral glucose load.

### Diabetic Patients

Diabetic patients are the most challenging group for FDG viability studies because insulin resistance impairs glucose-mediated FDG uptake. Higher insulin doses may be required, and the insulin clamp protocol is preferred. Blood glucose must be monitored carefully throughout preparation.

### Image Acquisition

Perfusion imaging is performed first using Rb-82, N-13 ammonia, or Tc-99m SPECT. FDG is then injected at 5 to 10 mCi (185 to 370 MBq) IV after metabolic preparation, followed by a 45 to 60 minute uptake period. PET acquisition is performed with ECG gating if possible to obtain concurrent functional data. FDG images are co-registered with perfusion images for mismatch analysis.

### Interpretation Patterns

#### Perfusion-Metabolism Mismatch (Viable)

Reduced perfusion with preserved or increased FDG uptake indicates hibernating myocardium. This is the hallmark pattern predicting functional recovery after revascularization. The larger the mismatch area, the greater the potential benefit from revascularization. Some studies suggest that a mismatch involving 10% or more of the LV myocardium is the threshold for meaningful survival benefit from revascularization.

#### Perfusion-Metabolism Match (Scar)

Proportionally reduced perfusion and FDG uptake indicates non-viable myocardium with scar or fibrosis. Revascularization is unlikely to improve function in matched segments, as this represents transmural scar.

#### Normal

Normal perfusion with normal FDG uptake indicates uninvolved myocardium with no evidence of ischemia or infarction.

#### Reverse Mismatch

Normal perfusion with reduced FDG uptake is a less common pattern that may represent subendocardial scar with maintained epicardial perfusion, or non-ischemic cardiomyopathy. Its clinical significance is less well defined.

## Tl-201 Viability Assessment

### Stress-Redistribution-Reinjection Protocol

Tl-201 is injected at peak stress, and initial images capture perfusion. At 3 to 4 hours, redistribution images are obtained: viable ischemic myocardium fills in as thallium redistributes from normally perfused regions. If a defect persists on redistribution, an additional 1 to 2 mCi of Tl-201 can be reinjected, followed by repeat imaging. Defects that fill in on redistribution or after reinjection are viable. Fixed defects after reinjection indicate scar, though approximately 50% of such segments may still demonstrate viability on FDG PET.

### Rest-Redistribution Protocol

This simpler protocol injects Tl-201 at rest with immediate imaging followed by delayed images at 3 to 4 hours (or 24 hours for late redistribution). Segments with initial defects that fill in on delayed images are viable. This protocol is used less frequently than FDG PET for viability assessment.

## Other Viability Methods (Non-Nuclear)

### Cardiac MRI -- Late Gadolinium Enhancement (LGE)

Cardiac MRI with late gadolinium enhancement has become the most commonly used viability method in many centers. The transmural extent of LGE predicts the likelihood of functional recovery: less than 25% transmural enhancement indicates high probability of recovery, 25 to 50% is intermediate, and more than 50% transmural enhancement predicts low probability of recovery (non-viable). Cardiac MRI offers excellent spatial resolution and is well validated, but it cannot be used in patients with severe renal insufficiency (due to gadolinium) or MRI-incompatible devices.

### Dobutamine Echocardiography

Low-dose dobutamine (5 to 10 mcg/kg/min) stimulates contractile reserve in viable myocardium. A biphasic response -- improvement at low dose followed by worsening at high dose -- indicates both ischemia and viability. Sustained improvement at both low and high doses indicates viability without significant ischemia. No improvement at any dose indicates scar. Dobutamine echocardiography is operator-dependent and limited in patients with poor acoustic windows.

## Controversy: Clinical Utility of Viability Testing

### STICH Trial

The Surgical Treatment for Ischemic Heart Failure (STICH) trial compared CABG plus medical therapy versus medical therapy alone in patients with ischemic cardiomyopathy and LVEF of 35% or below. The viability substudy found that viability assessment (by SPECT or dobutamine echocardiography) did not predict which patients would derive differential benefit from CABG. However, this finding has been widely criticized because viability was not used to randomize patients, the analysis was underpowered for detecting a viability-treatment interaction, and the viability testing methods were heterogeneous.

### PARR-2 Trial

The PET and Recovery Following Revascularization (PARR-2) trial compared FDG PET-assisted management versus standard care in ischemic cardiomyopathy. The primary endpoint was not significantly different overall. However, a post-hoc analysis found that patients who adhered to PET-guided treatment recommendations had better outcomes, suggesting that PET viability assessment has value when its results are actually followed.

### Current Practice

Viability testing remains guideline-recommended (AHA/ACC Class IIa) for selected patients with ischemic cardiomyopathy being considered for revascularization. It is most useful when the decision to revascularize is uncertain, particularly when a large territory of dysfunctional myocardium is present and surgical risk is elevated. FDG PET is considered the most sensitive viability method, detecting viability in segments that appear non-viable by other techniques. Cardiac MRI with LGE is increasingly the first-line modality at many centers because it does not require metabolic preparation. Ultimately, the decision to revascularize is clinical, with viability testing providing one important piece of the puzzle alongside coronary anatomy, comorbidities, and surgical risk assessment.

| Method | Principle | Sensitivity | Specificity | Key Advantage | Key Limitation |
|---|---|---|---|---|---|
| FDG PET | Glucose metabolism (mismatch) | 92% | 63% | Most sensitive; detects hibernation | Metabolic preparation complex |
| Tl-201 redistribution | K+ analog redistribution | 87% | 54% | Single tracer, no prep | High radiation dose; lower specificity |
| Dobutamine echo | Contractile reserve | 80% | 78% | No radiation; widely available | Operator-dependent; poor windows |
| Cardiac MRI (LGE) | Transmural scar extent | 95% | 51% | Best spatial resolution; no prep | Cannot use in severe CKD or devices |

<image>A panel of FDG PET viability images showing the three key interpretation patterns. Top row: perfusion images (Rb-82 or Tc-99m). Bottom row: corresponding FDG metabolic images. Pattern 1 (Mismatch): reduced anterior wall perfusion with preserved FDG uptake indicating hibernating myocardium. Pattern 2 (Match): reduced inferior wall perfusion with concordantly reduced FDG uptake indicating scar. Pattern 3 (Normal): normal perfusion with normal FDG uptake. Label each pattern with its clinical significance and management implication.</image>

<image>A comparison diagram of viability assessment methods showing FDG PET, Tl-201 rest-redistribution, dobutamine echocardiography, and cardiac MRI late gadolinium enhancement. For each method, illustrate the principle of detecting viable versus non-viable myocardium, sensitivity and specificity for predicting functional recovery, and key advantages and limitations. Highlight FDG PET as the most sensitive method and cardiac MRI LGE as offering the best spatial resolution.</image>

<image>An illustration of the metabolic preparation protocol for cardiac FDG PET viability imaging. Show the timeline: oral glucose load at time zero, blood glucose monitoring at 30-45 minutes, supplemental IV insulin if glucose elevated, FDG injection at 60 minutes after confirming adequate glucose level, 45-60 minute uptake period, then PET acquisition. Include a panel showing the effect of proper preparation (uniform myocardial FDG uptake) versus inadequate preparation (heterogeneous or absent myocardial uptake with high blood pool and fatty acid-dominant metabolism).</image>

## Clinical Pearls

The perfusion-metabolism mismatch pattern on FDG PET is the hallmark of hibernating myocardium. Reduced perfusion with preserved FDG uptake indicates viable tissue that can recover function after revascularization.

Patient preparation for cardiac FDG PET is critical. Without proper glucose loading, myocardial FDG uptake is unreliable. A technically inadequate preparation is the most common cause of non-diagnostic viability studies.

FDG PET is the most sensitive viability method, detecting viability in approximately 50% of segments that appear non-viable (fixed defect) on Tl-201 rest-redistribution imaging.

Diabetic patients are the most challenging population for FDG viability studies due to insulin resistance. The insulin clamp protocol is preferred, and higher insulin doses may be needed.

The STICH trial questioned the incremental value of viability testing for guiding revascularization decisions but has been criticized for significant methodologic limitations. Viability testing remains guideline-recommended when the revascularization decision is uncertain.

A mismatch area involving 10% or more of the LV myocardium is generally considered the threshold for meaningful benefit from revascularization.

Cardiac MRI with LGE has become the most commonly used viability method in many centers. More than 50% transmural enhancement predicts non-recovery, and the technique does not require the metabolic preparation that makes FDG PET challenging.

## References

- Beanlands RS, et al. F-18 fluorodeoxyglucose PET imaging-assisted management of patients with severe left ventricular dysfunction and suspected coronary disease (PARR-2). *J Am Coll Cardiol*. 2007;50(20):2002-2012.
- Bonow RO, et al. Myocardial viability testing and impact of revascularization on prognosis in patients with coronary artery disease and left ventricular dysfunction (STICH). *J Am Coll Cardiol*. 2011;57(2):190-198.
- Dilsizian V, et al. ASNC imaging guidelines/SNMMI procedure standard for PET nuclear cardiology procedures. *J Nucl Cardiol*. 2016;23(5):1187-1226.
- Ghosh N, et al. Role of FDG PET for myocardial viability assessment. *Heart Fail Clin*. 2016;12(3):411-424.